Oncolytics Biotech is a biopharmaceutical company that develops pharmaceutical products for cancer treatment, with a focus on solid tumors and hematological malignancies. Pelareorep is the company’s main product, which is delivered intravenously as an immunotherapeutic agent. The biotech firm has a co-development agreement with Pfizer and Merck KGaA to co-develop pelareorep, in combination with avelumab and paclitaxel for metastatic breast cancer.